MRSA Research Today is a free monthly online journal that collates and summarizes the latest research about MRSA, including details on methicillin-resistant staphylococcus aureus, hospitals, infection, antibiotic resistance, superbugs.

Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.

Skiest DJ

Baystate Medical Center, Division of Infectious Diseases, 759 Chestnut St., Springfield, MA 01199, USA. daniel.skiest@bhs.org

Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of infections by gram-positive organisms, including infections with methicillin-resistant Staphylococcus aureus (MRSA). A patient infected with infected with MRSA developed resistance to daptomycin after prolonged exposure, which resulted in clinical failure. Clinicians should be aware of the possibility of daptomycin resistance and should consider routine testing for daptomycin susceptibility.

Published 3 February 2006 in J Clin Microbiol, 44(2): 655-6.
Full-text of this article is available online (may require subscription).

© 2004-2008 MRSA Research Today. All Rights Reserved.